Strokes are commonly known as "strokes."
If it happens, it must be taken to the hospital immediately.
Missing the "golden period" of treatment can be life-threatening.
Can you get stroke meds stocked up ahead of time
Give brain protection in the first place?
There's a new drug that solves this problem
Takes effect quickly when taken under the tongue
Effective in reducing brain cell mortality
Extending the "window of time" for stroke treatment.
More room for doctors to save lives
Recently, Nanjing Jiangbei New Area enterprises Sage Pharmaceuticals came to the good news:Its innovative drug Symbicort® Sublingual Tablets (generic name: Edaravone Dexamfetamine Sublingual Tablets) for the treatment of stroke was approved for marketing by the State Drug Administration.
which improves neurological symptoms, activities of daily living and functional impairments due to acute ischemic stroke.In the future, it will be available for purchase in hospitals on prescription and will also be available online at Internet hospitals.
Stroke, commonly known as "stroke", is the leading cause of death and disability in China. Strokes are divided into ischemic strokes and hemorrhagic strokes, with more than 60% of strokes in China being ischemic strokes, or "cerebral infarctions," in which blood fails to flow to the brain due to a blockage in a blood vessel; hemorrhagic strokes refer to bleeding caused by sudden rupture of a blood vessel in the brain. Both types of strokes cause damage to brain tissue, leading to disability or death after clinical symptoms appear.
In 2020, Centrum Pharmaceuticals had been approved to market a drug for the treatment of stroke, Centrum® Injection. The drug is the only innovative drug approved in the field of stroke worldwide since 2015, and has helped more than 3 million stroke patients cumulatively.
However, Symbicort® Injection requires patients to be treated in the hospital with infusions, and strokes are sudden.How to make the product more convenient and timely to use in order to expand to the whole process of patient onset, hospitalization, discharge home treatment and rehabilitation?In 2016, the R&D team of Centrum Pharmaceuticals started to explore the development of the sublingual tablet dosage form of Centrum®.
"It's a brand new dosage form that works by placing the drug under the tongue, where it rapidly disintegrates when it comes into contact with saliva and is absorbed into the bloodstream and brain through the sublingual venous plexus."Relevant staff of Centrum Pharmaceuticals said, "Compared with the general oral drug dosage form, sublingual tablets do not need to be metabolized and attenuated by the liver, and can be more fully absorbed and utilized by the body."
The innovative drug delivery method allows patients to take the drug at the first time after a stroke occurs to protect brain cells in time, and it is also convenient to take the drug at home after being discharged from the hospital, which increases the flexibility of stroke treatment modality and obtains earlier rescue treatment and a more adequate course of treatment.
In addition to a more convenient way of taking the medication, Symbicort® sublingual tablets are also guaranteed to be effective.
The drug, developed by Symphony Pharmaceuticals in cooperation with Nintan Pharmaceuticals, is a dual-targeted brain cell protection agent containing two active ingredients, edaravone and dexamethasone, which synergize antioxidant and anti-inflammatory effects. As an important research result of the National Key Laboratory of Neurology and Tumor Drug R&D, theClinical studies of this drug have shown that Symbicort® sublingual tablets significantly reduce brain cell damage caused by acute ischemic stroke.
In the future, Symbicort® sublingual tablets are expected to be expanded to emergency stroke medication.Research shows that the recurrence rate of patients after stroke is 10%-15% in the first year, and 25%-40% within 5 years, and the recurrence rate of death and disability is even higher, so the patients urgently need to get brain cell protection in the first time. In addition, China's three-high population of more than 400 million, overweight and obese population of more than 600 million, 350 million smokers, these high-risk groups also need to be always on hand for emergency stroke medication.
"Just like nitroglycerin for heart patients, a patient with a Symbicort® sublingual tablet immediately after a stroke has a lower brain cell death rate and gives doctors more room to save their lives.The future holds the promise of distributing Symbicort® sublingual tablets like nitroglycerin to families and to the pillows of at-risk individuals."Wang Congjun, director of the National Medical Control Center for Neurological Diseases and president of Beijing Tiantan Hospital of Capital Medical University, said.Chinese researchers' "Chinese solution" to the world problem of brain cell protection is also expected to blossom in the United States.
In August of this year, Symbicort® sublingual tablets were recognized by the U.S. Food and Drug Administration (FDA) as a "breakthrough therapy".It is the first innovative drug in the field of stroke treatment in the world to receive this recognition, and the first innovative drug in the field of neuroscience in China to receive this recognition.A global multicenter clinical study of Symbicort® sublingual tablets is currently in preparation.
